News and Events



Romer Labs Seminar: New Developments in Allergen Management and Cleaning

Romer Labs Seminar: New Developments in Allergen Management and Cleaning

Posted 11 May 2020

The prevalence of food allergies has been increasing in recent decades worldwide. It is of upmost importance to not only have correct product labelling, but also to establish appropriate allergen management programmes to ensure no cross-contamination occurs in production facilities. In this webinar, Romer Labs will lead a discussion on new updates in allergen management and... Read more

Important Update: AMSL's Commitment during COVID-19

Posted 24 Mar 2020

Important Message from AMSL General Manager, Ian Slater on COVID-19 The impact of COVID-19 has been unprecedented as it continues to affect people and organisations around the world. The Federal Government, State Governments and Health Authorities continue to provide detailed guidelines on how to mitigate risks and ensure containment. We encourage all of our customers to review these... Read more

AMSL Medical Portfolio Expands in 2020

Posted 20 Mar 2020

The Return of the ACE Stopper!AMSL Medical are pleased to announce that the Medicina ACE Stopper is now available for supply, back by popular demand. Medicina ACE Stoppers are small, implant grade silicone stoppers, that are used to seal stoma sites at various parts of the body. All 12 ACE Stopper sizes along with the Caecostomy Extension Set are available now and... Read more

Dexcom G6 CGM System Update

Posted 2 Mar 2020

We are delighted to announce that the Dexcom G6 Continuous Glucose Monitoring (CGM) System, has been registered in Australia (ARTG 330535).   Dexcom G6 represents the latest addition to the AMSL Diabetes product range, which includes the Dexcom G5 Mobile CGM, Tandem t:slim X2™ insulin pump, V-Go insulin patch pump for type 2 diabetes, Lifescan... Read more

The Australian Government Simplifies the Clinical Eligibility Criteria for the Continuous Glucose Monitoring (CGM) Initiative

Posted 2 Mar 2020

From the 1st of March, 2020, the Australian Government is simplifying the clinical eligibility criteria for the Continuous Glucose Monitoring (CGM) Initiative. This will allow people with type 1 diabetes under the age of 21, and those over the age of 21 who have valid concessional status to access fully subsidised CGM devices through the National Diabetes Services Scheme (NDSS).... Read more

AMSL Medical attends Global Collatamp G Seminar in Paris, France

Posted 18 Feb 2020

On January 27th - 29th 2020, National Sales Supervisor, Amy Antenucci, attended the 1st global Collatamp G seminar in Paris, France. The interactive meeting aimed to extend the knowledge on Collatamp G and share best practice among delegates. Hosted by SERB, the global distributor of Collatamp G, the meeting was attended by representatives from Europe, UK, South Korea, Singapore,... Read more

AMSL Point of Care Recognised at Global Horizon Distributor Meeting with 'Best Percentage Growth in Sales'

Posted 12 Feb 2020

AMSL Point of Care have been awarded ‘Best Percentage Growth in Sales’ and ‘Best Practice Selling Whole Portfolio’ at the Global Horizons Distributor Meeting in Bangkok in October 2019. AMSL Point of Care are the Australian distributors of Nova Biomedical products such as StatStrip® Glucose/Ketone and Lactate meters as well as the StatProfile Prime... Read more

AMSL Diabetes partner with MannKind Corporation

Posted 17 May 2019

Sydney, Australia, May 2019 – AMSL Diabetes are excited to announce that they have signed a distribution agreement with MannKind Corporation (NASDAQ: MNKD) to introduce their patient-focused therapies to the Australian market. The exclusive partnership is set to benefit Australian diabetes patients by offering a new innovative technology solution to their diabetes management.... Read more

AMSL Diabetes to distribute MedAngel ONE in Australia

Posted 3 Apr 2019

Sydney, Australia, April 2019 – AMSL Diabetes are delighted to announce that they have agreed to distribute MedAngel products in Australia. MedAngel aims to empower patients with intuitive technology to assist them in monitoring the temperature of their temperature-sensitive medications such as insulin. AMSL Diabetes will be distributing MedAngel ONE, a Bluetooth® temperature... Read more

The Australian Government announces Continuous Glucose Monitoring (CGM) Subsidy Initiative Expansion

Posted 1 Mar 2019

 The Australian Government is extending access to fully subsidised continuous glucose monitoring (CGM) products through the National Diabetes Services Scheme (NDSS) to now include eligible patients aged over 21 years with type 1 diabetes. Previously, only patients aged 21 years or under were eligible for subsidised CGM.  Both Dexcom G5 Mobile and Dexcom G4 PLATINUM Systems are now... Read more

NDSS Blood Glucose Strips Review Press Release

Posted 15 Nov 2018

Inclusion of OneTouch Verio Blood Glucose Test Strips on the new National Diabetes Services Scheme (NDSS) Product Schedule ­­­­­­­­­­­___________________________________________________________________ Sydney, Australia, November 2018 – The Australian Government recently undertook a review of certain products on the NDSS Product Schedule, with the... Read more

AMSL Diabetes partner with Tandem Diabetes Care, Inc.

Posted 24 Apr 2018

AMSL Diabetes announce new partnership with Tandem Diabetes Care in Australia. AMSL Diabetes are delighted to announce they have partnered with Tandem Diabetes Care®, Inc. to introduce their innovative product range to the Australian market for the very first time. The exclusive partnership is set to benefit Australian type 1 diabetes patients by offering them a new leading edge choice for... Read more

AMSL signs exclusive distribution agreement with Valeritas Holdings, Inc.

Posted 18 Apr 2018

AMSL announces distribution agreement with Valeritas Sydney, Australia, April 18, 2018 --- AMSL Diabetes are pleased to announce they have signed an exclusive distribution agreement with Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company which offers patients with type 2 diabetes products to help their day to day insulin management. Under the terms of the agreement, AMSL... Read more

CDR FoodLab, BeerLab and WineLab is now available in Australia!

Posted 24 Jan 2018

Distributed by AMSL Scientific, CDR FoodLab analysis systems provides onsite chemical analyses for food and beverage quality control, with high accuracy and sensitivity. With just one device, CDR FoodLab allows the user to analyse 16 samples or several analytical parameters at the same time, in just a number of minutes. This can be performed entirely in-house, without the need of external... Read more

StatStrip Lactate - The first POC meter in Australia to be officially cleared for use in Foetal Scalp Lactate testing

Posted 10 Jan 2018

The StatStrip Lactate Xpress and Connectivity Meter is the first POC meter in Australia to be officially cleared for use in foetal scalp lactate testing in birthing suites. This is documented in the updated ARTG certificate.  For more information on the StatStrip Lactate Meter, visit here or contact our POC team on 1300 845 762. Read more

StatStrip Glucose/Ketone Meters are officially cleared for Critical Care Use in Australia

Posted 4 Jan 2018

AMSL Point of Care is very excited to announce that the StatStrip Glucose/Ketone Meters are officially cleared for use in Critical Care settings (ICU, ED, NICU etc.) and documented within the updated ARTG Certificate. This makes StatStrip the only Point of Care Glucose meter currently on the market that is cleared for use in Critically ill patients in Australia. For more information on... Read more

Dexcom Continuous Glucose Monitoring (CGM) now available on the Government Subsidy Initiative

Posted 8 May 2017

The Australian Government is now providing access to fully subsidised continuous glucose monitoring (CGM) products through the National Diabetes Services Scheme (NDSS). Subsidised access to Dexcom G5 Mobile and Dexcom G4 PLATINUM CGM sensors and transmitters is available through the NDSS to children and young people aged under 21 years, living with type 1 diabetes, who meet specific criteria.... Read more